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Background: In addition to protection against the target diseases, vaccines may have non-specific effects
(NSEs). Measles vaccine (MV) has beneficial NSEs, providing protection against non-measles deaths, most
so for girls. By contrast, though protecting against diphtheria, tetanus and pertussis, DTP vaccine is
associated with increased female mortality relative to male mortality. In 2008, Guinea-Bissau replaced
DTP with the DTP-containing pentavalent vaccine (Penta; DTP-H. influenza type B-Hepatitis B) at 6, 10
and 14 weeks and yellow fever vaccine (YF) was to be given with MV. We investigated possible
sex-differential mortality rates following Penta and MV+YF vaccination.
Methods: Bandim Health Project (BHP) registers vaccines given by the three government health centres
in the study area and vital status through demographic surveillance. We assessed the association
between sex and mortality by vaccination status in Cox proportional hazards models with age as
underlying timescale. Follow-up was censored at a subsequent vaccination contact or after 6 months
of follow-up.
Results: Between September 2008 and April 2011, we registered 23,448 vaccination contacts for children
aged 42–365 days; 17,313 were for Penta and 3028 for MV (2907 co-administered with YF). During
follow-up 112 children died. The female/male mortality rate ratio was 1.73 (1.11–2.70) following
Penta and 0.38 (0.12–1.19) after MV (p = 0.02 for same effect). Adjusting for maternal education or
weight-for-age at the time of vaccination did not change the estimates.
Conclusion: Penta appears to have the same negative effects on mortality as those seen for DTP. Assessing
post-vaccination mortality for boys and girls is necessary to improve the vaccination programme.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccines are given to prevent specific infections but there is
increasing evidence that vaccines may have much broader effects
on overall child health [1]. The effects which are not explained
by specific disease prevention have been named ‘‘non-specific” or
‘‘heterologous”. While disease-specific immune memory may
not be altered by administration of subsequent vaccines, thenon-specific effects (NSEs) are shaped most strongly by the most
recent vaccination [2–4].
The NSEs can be beneficial but also harmful. The live Bacillus
Calmette-Guerin (BCG) and measles vaccine (MV) are associated
with beneficial NSEs improving overall child survival [5–12]. How-
ever, though protecting against the targeted infections, the inacti-
vated diphtheria-tetanus pertussis vaccines (DTP) is associated
with higher child mortality [3,5,12–17]. NSEs are often sex-
differential; while MV has been associated with stronger beneficial
effects for girls than for boys, DTP has been linked to higher female
mortality [2,3,6,13,18,19]. In low-income countries, vaccines are
recommended sequentially during infancy: BCG vaccine at birth,
three doses of DTP-containing vaccine at 6, 10 and 14 weeks of
age and a MV at 9 months of age. If DTP and MV have strong effects
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most recent vaccine should lower the female/male mortality rate
ratio (F/M MRR). In 2007 this lead to the formulation of the
hypothesis, that the transition from DTP to MV should result in
an inversion of the F/M MMRs [20].
During the last 10 years the DTP-containing pentavalent vac-
cine (‘‘Penta”: DTP-H. influenza type B-Hepatitis B) has replaced
DTP [21] and yellow fever vaccine (YF) has been introduced to be
co-administered with MV [22] in many low-income countries.
Hence, we investigated whether the F/M MRR after Penta and after
MV+YF were similar to the effects previously reported for DTP and
MV.2. Methods
2.1. Setting and population
Bandim Health Project (BHP) runs a Health and Demographic
Surveillance system (HDSS) in six suburban districts in Bissau,
the capital of Guinea-Bissau. The HDSS covers a population of
100,000 individuals. All households are visited monthly to enquire
about pregnancies and deaths. At the first visit after birth informa-
tion on socioeconomic status is collected. The indicators include
maternal characteristics (education and ethnicity) and household
characteristics (type of roofing, availability of bathroom and elec-
tricity). Children below the age of 3 years are visited every
3 months to collect information on vital status as well as vaccina-
tions, hospitalisations and nutritional status.2.2. Assessment of exposure
Since the end of August 2008, the national Expanded Pro-
gramme on Immunizations (EPI) vaccination schedule in Guinea-
Bissau is BCG and OPV at birth, Penta with OPV at 6, 10 and
14 weeks and MV and YF vaccine at 9 months of age [23]. Vaccina-
tions are administered at the three health centres in the study area
and during outreach campaigns with occasional vaccination posts
outside the health centres. A BHP-assistant records all vaccinations
and weighs all children presenting for vaccination using an elec-
tronic scale (SECA 835/SECA 336).2.3. Assessment of outcome
Mortality was assessed at all home visits. After registration of a
death a verbal autopsy [24] was conducted by a trained field assis-
tant. A medical doctor subsequently reviewed the collected infor-
mation to assess the cause of death.2.4. Interventions taking place during the study period
A full list of campaigns with vitamin A and vaccinations which
were conducted during the study period is provided in Supplemen-
tary Table 1. In July 2009, children aged 9 months-5 years received
MV; OPV was given to children 0–5 years in March, April and May
2010 and in March and April 2011. In October 2010 an H1N1 influ-
enza vaccination campaign targeted children aged 6 months to
5 years.
Three randomised trials (RCTs) could have affected the study
cohort. One RCT compared OPV+BCG vs BCG-only among normal
birth weight children (enrolled neonates between July 2008 and
October 2011) [25]; another RCT compared delayed BCG (current
practice) vs. BCG at birth to low birth weight children (enrolled
neonates between February 2008-September 2013) [26]. A third
RCT compared vitamin A supplementation (VAS) versus placeboat vaccination contacts after 6 months (enrolled children aged 6–
23 months between August 2008-December 2009) [27].
2.5. Epidemiological and statistical methods
Our main interest was the F/M-MRR after Penta (which was
defined as a Penta ±OPV) and MV+YF, respectively. A child resident
in the BHP HDSS and aged 42 and 365 days could enter the analysis
on the date of vaccination at a health centre/outreach post in the
study area. We excluded vaccination contacts at which VAS was
given, as it was pre-specified that the hypothesis regarding
female-male differences in mortality after DTP and MV should be
tested in settings where no other interventions were given [20]
and we have shown in many previous studies that vitamin A and
vaccines interact [28–30].
Baseline characteristics were compared by sex within vaccine
groups. We calculated a weight for age-Z-score (WAZ) for the vac-
cinated children using the 2006-WHO child growth standard [31]
and the WHO Anthro version 3.2.2 macro for Stata [32].
We compared the survival of girls and boys in Cox-proportional
Hazards models with age as the underlying timescale. Children
entered the survival analysis at dates of vaccination between 1
September 2008 and 18 April 2011. The study was terminated at
18 April 2011 because children receiving Penta after this date were
likely to enter a RCT of early MV at 4.5 months of age (clinicaltri-
als.gov, NCT 01486355). Analyses were conducted using Stata13.0.
As discussed above, the NSEs are strongest for the most recent
vaccine. Therefore a child contributed survival time with a given
vaccine until the reception of a subsequent vaccine or for a maxi-
mum of 6 months, as pre-specified in the hypothesis [20]. Hence,
follow-up was censored when children received a different vac-
cine. The children could re-enter the analysis in a new vaccination
group according to a subsequently received vaccine. All analyses of
Penta were additionally censored at 9 months of age, since children
become eligible for MV at 9 months of age, and prolonging follow-
up beyond that date would inevitably accumulate more follow-up
time in children who were delayed for MV compared with children
who received MV, creating the possibility for selection bias. Fur-
thermore, we additionally censored at the first vaccination cam-
paign occurring during the follow-up period. We stratified the
analysis for participation in one of the neonatal trials. Previous
studies have suggested, that early administration increases the
negative effect of DTP [3,33]. In the 1980s, DTP was only given
from 3 months of age [14]; we assessed whether sex-differential
mortality patterns after Penta depended on age at vaccination.
Finally, we assessed whether excluding the first 4 months after
the introduction of Penta and YF, where outreach campaigns were
frequent and children received vaccines out of sequence, altered
the results.
These analyses are based on children who presented for vacci-
nation at the health centres/outreach posts in the study area. To
obtain an estimate of the F/M MRR among children who were unli-
kely to have been Penta-vaccinated, we compared mortality by sex
among children who had not (yet) presented for any vaccination
after 42 days. This was done by linking the routine surveillance
database with the health centre vaccination records, allowing all
children under BHP surveillance between 1st September 2008 to
18th April 2011 to contribute to the analysis. In this analysis, chil-
dren contributed time at risk between whichever came last: date of
registration, date of birth and 1st September 2008, and until
whichever came first: any registered vaccination contact after
42 days, migration or death. We compared mortality of girls to
the mortality of boys in a Cox-proportional hazards model with
age as underlying timescale. The F/M MRR was estimated in three
age intervals: birth to 41 days, 42 days to 8 months and 9
(274 days) to 18 months. In the age group ‘‘birth to 41 days” the
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Fig. 1. Number of vaccination contacts by vaccine and calendar time. Number of
registered vaccination contacts with children aged 42–365 days registered in the
Bandim Health Projects urban HDSS, 1st September 2008 – 18th April 2011. Penta:
Pentavalent vaccine: diphtheria-tetanus-pertussis, H. influenza type B and Hepatitis
B. MV: Measles vaccine. OPV: Oral Polio Vaccine. Category Penta includes
Penta ± OPV; Category MV includes MV ± yellow fever vaccine.
A.B. Fisker et al. / Vaccine 34 (2016) 4551–4557 4553children were likely to have received BCG and OPV0. Among the
older children they are likely to be Penta-(and measles-)
unvaccinated because we censor for vaccination contacts after
42 days; however not all children are vaccinated at the healthTable 1
Background variables by sex among children vaccinated with pentavalent or measles and
Penta ± OPV
Boys Girls P-v
Number 8790 8523
Median age (IQR) 96 (61–133) 96 (61–133) 0.8
Place of residence
Bandim1+2 4046 (46) 3803 (45) 0.1
Belem+Mindara 1283 (15) 1316 (15)
Cuntum1+2 3459 (39) 3401 (40)
Ethnicity
Pepel 2510 (29) 2460 (29) 0.0
Fula/Mandinga 2445 (28) 2365 (28)
Manjaco/Mancanha 1600 (18) 1423 (17)
Other 2188 (25) 2248 (26)
Missing information 47 27
Maternal schooling
None 2018 (24) 2105 (26) 0.0
Primary (1-4 years) 1212 (15) 1149 (14)
Secondary (>5 years) 5096 (61) 4717 (59)
Missing information 464 552
Housing
Type of roof
Straw 189 (2) 205 (2) 0.2
Hard 8530 (98) 8240 (98)
Missing information 71 78
Toilet facilities
None 2 (0) 8 (0) 0.0
Latrine 7407 (85) 7206 (85)
Inside 1307 (15) 1220 (14)
Missing information 74 89
Electricity
Yes 2457 (28) 2369 (28) 0.8
No 6254 (72) 6073 (72)
Missing information 79 81
Weight for age (WAZ)
Mean WAZ (SD) 0.33 (1.17) 0.36 (1.10) 0.1
Missing information 114 137
a P-value for test of no difference in background factors between boys and girls.centres and some may therefore have been vaccinated with Penta
and MV elsewhere.
2.6. Role of the funding source
The funders had no role in study design, data collection and
analysis, preparation of the manuscript, or decision to publish.3. Results
Between September 1, 2008 and April 18, 2011, 23,248 vaccina-
tion contacts for 8730 children aged 42–365 days were registered
by BHP assistants in the urban study area. Eight hundred children
received high-dose VAS at enrolment in an RCT [27] and were
excluded from the present study. At the remaining 22,448 contacts,
77% (17,313) received a Penta (85% (14,747) with OPV), 13% (3028)
MV and YF vaccines, 6% (1379) OPV-only and 1% (271) Penta with
MV and YF (Fig. 1). Smaller groups of children received other
combinations of vaccines (Supplementary Table 2) and were not
considered further.
Background characteristics for the two main groups, Penta and
MV+YF, are shown in Table 1. The distribution of children in the
two vaccination groups did not differ by sex (p = 0.60). Within
the vaccination groups, age at vaccination and place of residence
did not differ by sex. There were no systematic differences by
sex in other background factors (Table 1). Information on weight
was missing for 2% (368/20,341) of the vaccination contacts. Theyellow fever vaccines.
MV ± YF
aluea Boys Girls P-valuea
1553 1475
6 287 (278–303) 288 (278–303) 0.32
2 646 (42) 612 (41) 0.99
231 (15) 221 (15)
673 (43) 642 (44)
2 463 (30) 424 (29) 0.39
334 (22) 339 (23)
318 (21) 274 (19)
432 (28) 432 (29)
6 6
1 295 (20) 319 (23) 0.14
214 (14) 198 (14)
980 (66) 882 (63)
64 76
6 38 (2) 38 (3) 0.82
1504 (98) 1425 (97)
11 12
9 1 (0) 3 (0) 0.56
1286 (84) 1215 (83)
253 (16) 244 (17)
13 13
3 459 (30) 423 (29) 0.58
1079 (70) 1040 (71)
15 12
3 0.41 (1.18) 0.31 (1.11) 0.03
65 52
Table 2
Mortality following vaccination contacts in urban Guinea-Bissau, 2008–11.
Vaccine Sex Rate per 1000 PYRS
(Deaths/PYRS)
Female/male mortality rate ratio
(95% CI)
P-valuea Female/male mortality rate ratio
(95% CI)b
P-valuea
Penta Boys 15.5 (31/1,999) 1.73 (1.11–2.70) 0.02 1.86 (1.16–2.98) 0.01
Girls 26.8 (52/1,939)
MV+YF Boys 14.8 (11/745) 0.38 (0.12–1.19) 0.38 (0.12–1.21)
Girls 5.6 (4/716)
Penta+MV+YF Boys 19.4 (1/52) 0.99 (0.06–15.83) 1.07 (0.07–17.19)
Girls 18.7 (1/54)
OPV Boys 33.1 (5/151) 1.16 (0.33–3.99) 1.17 (0.34–4.03)
Girls 38.3 (5/130)
Censoring at 9 months for Penta
Penta Boys 16.1 (28/1,738) 1.55 (0.96–2.49) 0.03 1.69 (1.02–2.82) 0.02
Girls 24.9 (42/1,686)
MV+YF Boys 14.8 (11/745) 0.38 (0.12–1.19) 0.38 (0.12–1.20)
Girls 5.6 (4/716)
Censoring at 9 months for Penta + at vaccination campaigns
Penta Boys 11.9 (13/1,089) 1.66 (0.95–2.91) 0.12 1.78 (0.98–3.24) 0.11
Girls 25.7 (27/1,049)
MV+YF Boys 6.5 (2/307) 0.27 (0.03–2.42) 0.27 (0.03–2.45)
Girls 3.5 (1/283)
a P-value for test of same effect of sex in Penta and MV+YF groups.
b Adjusting for maternal education reduced the number of deaths by 8, all in the Penta group (4 boys and 4 girls).
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Fig. 2. Cumulative mortality according to sex and reception measles and yellow
fever or Pentavalent vaccines. Cumulative mortality for children presenting for
vaccination with Pentavalent vaccine (Penta: diphtheria-tetanus-pertussis-H.
influenza type B, Hepatitis B with or without oral polio vaccine) or measles vaccine
(with or without yellow fever vaccine; MV+YF) at age 42–365 days. Follow up for up
to 6 months or until reception of a subsequent vaccine.
Table 3
Mortality following vaccination contacts in urban Guinea-Bissau according to number
of Penta vaccines received.
Vaccine Sex Rate per 1000
PYRS (Deaths/
PYRS)
Female/male
mortality rate
ratio (95% CI)
Adjusted female/
male mortality rate
ratio (95% CI)a
Penta1 Boys 18.9 (10/529) 1.40 (0.61–3.20) 1.41 (0.62–3.23)
Girls 26.2 (13/497)
Penta2 Boys 21.0 (10/475) 2.16 (1.02–4.57) 3.20 (1.28–8.02)
Girls 46.1 (22/477)
Penta3 Boys 11.1 (11/994) 1.59 (0.74–3.39) 1.52 (0.71–3.28)
Girls 17.6 (17/966)
Censoring at 9 months
Penta1 Boys 19.2 (10/520) 1.28 (0.55–2.97) 1.31 (0.57–3.04)
Girls 24.4 (12/492)
Penta2 Boys 23.9 (10/419) 1.72 (0.79–3.73) 2.43 (0.94–6.27)
Girls 41.5 (18/434)
Penta3 Boys 10.0 (8/799) 1.57 (0.64–3.84) 1.59 (0.65–3.90)
Girls 15.8 (12/760)
Censoring at 9 months for Penta + at vaccination campaigns
Penta1 Boys 19.5 (8/410) 1.22 (0.47–3.15) 1.23 (0.48–3.19)
Girls 23.4 (9/384)
Penta2 Boys 18.0 (6/333) 2.34 (0.90–6.08) 3.74 (1.04–13.41)
Girls 42.2 (14/332)
Penta3 Boys 10.8 (6/558) 1.55 (0.55–4.37) 1.58 (0.56–4.43)
Girls 16.8 (9/535)
a Adjusting for maternal education reduced the number of deaths by 8, all in the
Penta group (3 boys and 1 girl after Penta2, 1 girl after Penta3).
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+YF-group, while there were no other significant differences by
sex. The median age of vaccination did not differ by sex for Penta1,
Penta2 or Penta3 (Supplementary Table 3).
During 6 months of follow-up 112 deaths occurred and verbal
autopsies were conducted for 101; 11 families had moved away
before a verbal autopsy could be conducted. Two deaths were
due to injuries/accidents and were censored on the date of death
(1 boy, Penta; 1 boy, MV+YF). The main causes of death were
malaria (35%), gastro-intestinal infections (22%) and respiratory
infections (15%) (Supplementary Table 4).
There were 83 non-accident deaths following Penta, 52 girls
and 31 boys resulting in a F/M MRR of 1.73 (1.11–2.70). Among
recipients of MV and YF 4 girls and 11 boys died, the F/M MRR
being 0.38 (0.12–1.19). The inversion in the F/M MRR was statisti-
cally significant, p = 0.02 (Table 2, Fig. 2). Adjusting for maternal
education had little effect (F/M MRR = 1.86 (1.16–2.98) after Pentaand 0.38 (0.12–1.21) after MV+YF (p = 0.01 for interaction between
vaccine type and sex)). Adjusting for WAZ and for participation in
one of the neonatal trials also made no difference (data not shown).
Censoring follow up at 9 months of age or at the first campaign
revealed the same patterns (Table 2).
The F/M MRR after Penta was 1.03 (0.48–2.22) for deaths
classified as due to malaria, but 2.24 (1.28–3.92) for other
non-accident deaths; 2.82 (0.90–8.86) for gastrointestinal deaths;
1.55 (0.44–5.51) for respiratory infections and 7.22 (0.89–58.6)
for septicaemia.
Though not statistically significant, the sex-differential mortal-
ity may have been slightly stronger after Penta2 (F/M MRR = 2.16
(1.02–4.57)) and Penta3 (F/M MRR = 1.59 (0.74–3.39)) than after
penta1 (F/M MRR = 1.40 (0.61–3.20)) (Table 3). The F/M MRR was
A.B. Fisker et al. / Vaccine 34 (2016) 4551–4557 45551.85 (1.08–3.15) for children Penta-vaccinated before 3 months of
age, and 1.49 (0.66–3.36) for those vaccinated later.
Most Penta vaccines (85%, 14,747/17,313) were
co-administered with OPV and we observed no sex-difference in
the small group which received Penta only with 6 months of
follow-up (Supplementary Table 5). Limiting the analysis to
the children vaccinated in 2009–11, the F/M MRR was 2.00
(1.23–3.28) (47 girls, 24 boys) after Penta. In the MV+YF group
the F/M MRR was 0.46 (0.14–1.50) (4 girls, 9 boys) (p = 0.02 for
interaction between vaccine and sex) (Supplementary Table 6).
A total of 12,580 children were under surveillance between
0–18 months in the BHP HDSS between 1st September 2008 and
18th April 2011. Mortality was higher for boys than for girls
between birth and 41 days (F/M MRR = 0.69 (0.53–0.90)). Among
children for whom no vaccination contact after 42 days had yet
been registered, mortality did not differ by sex between 6 weeks
and 8 months (F/M MRR = 1.07 (0.66–1.75)) nor between 9 months
and 18 months: 1.18 (0.55–2.55) (Supplementary Table 7).4. Discussion
4.1. Main results
Female mortality was higher than male mortality after Penta
and mortality declined much more for girls than for boys after
MV+YF. Hence, the addition of HiB and hepatitis B has not altered
the sex-differential mortality effect of DTP. Thus, the hypothesis
put forward in 2007, that the transition from DTP to MV should
result in an inversion of the F/M MMRs [20], was confirmed also
for Penta and MV+YF.4.2. Strengths and weaknesses
We have compared survival of girls and boys after vaccination
with Penta and MV+YF. Since the NSEs are more pronounced for
girls than boys and work in opposite directions for the two vaccine
groups assessed [13,34], this provides a method to examine the
NSEs in an unbiased way. It is clearly not random who is vacci-
nated and unvaccinated, but by comparing mortality according to
sex, we avoid comparing two groups who are differently selected
at baseline. Of course the study design would be flawed if there
were differences in how early boys and girls were vaccinated but
we have found no indication that age of vaccination differed by
sex (Table 1, Supplementary Table 3). Adjusting for the background
factors which differed slightly between males and females had no
impact on the estimates.
The present study used vaccination data collected at health cen-
tres and outreach posts in urban Guinea-Bissau, thus obtaining the
information on vaccine exposure from the date of administration.
The BHP staff registering vaccinations was carefully trained and
intensively supervised, thus misclassification of vaccination status
is unlikely. Only children who could be followed through the BHP
HDSS were included in the analyses. In a supplementary analysis,
we compared mortality of girls and boys for whom no vaccination
contact had yet been registered after 42 days. While this analysis
includes unvaccinated children, it is important that the F/M MRR
in this group is not interpreted as the F/M MRR among unvacci-
nated children. BCG and OPV is recommended at birth and most
children will have received these vaccines. By censoring at first
registered vaccination contact after 42 days, we censor most chil-
dren as they receive Penta (and OPV and/or MV). However, vacci-
nes are available elsewhere, and some children for whom no
vaccination was registered may have been vaccinated elsewhere.
The difference in the F/M MRR in Penta vaccinated children and
predominantly Penta-unvaccinated children is likely to reflect theeffect of Penta on the relative mortality of females and males.
However, a comparison of the mortality rates in the two cohorts
is unlikely to reflect the effect of Penta vaccination. The age of
entry in the cohorts differed: Children in the predominantly
Penta-unvaccinated cohort entered on 42 days of age, while chil-
dren entered the main analysis of Penta-vaccinated children at
96 days (Table 1). In addition, we would expect children who enter
the main analysis to have a lower mortality risk as it is the health-
ier and better off children who are vaccinated first [3].
4.3. Consistency with previous studies
The hypothesis that transition from DTP to MV should result in
an inversion of the F/M MRR [20] has been tested and confirmed in
a number of studies [13,35]. The present study is the first to test
whether the pattern also holds true, when two additional antigens
have been added to DTP and when YF is co-administered with MV.
We found that Penta was associated with a F/M MRR of 1.86 (1.16–
2.98) when adjustment was made for background factors. We have
recently reviewed the 16 studies reporting the F/M MRR after DTP
[35] and the meta-estimate was 1.50 (1.21–1.85) times higher
mortality for females, quite similar to the present estimate. A
recent review prepared for WHO’s Strategic Advisory Group of
Experts on Immunization (SAGE) [36] found limited evidence for
sex-differences in the mortality response to DTP. However, the
SAGE review tested the hypothesis of higher female than male
mortality indirectly by contrasting the effect of DTP versus no
DTP in girls and boys, rather than comparing the F/M MRRs among
DTP vaccinated children as the hypothesis had specified [20]. By
limiting the review to studies which also had information on mor-
tality in DTP-unvaccinated children, many studies were excluded.
Furthermore, even though it had been specified that studies with
survival bias should not be used [20], the SAGE review assumed
that biases for girls and boys would cancel out [36] and therefore
included studies with survival bias and frailty bias [35,37]. Hence,
the SAGE review included uncertain data points and did not
include all relevant estimates of sex-differences in mortality
among DTP-vaccinated children [35].
The mortality rate for MV+YF vaccinated girls was reduced to
almost a 5th of the rate observed after Penta, while boys had only
a slight reduction in mortality rate (Table 2). The limited difference
in mortality rate between the two age groups for boys is similar to
observations from the pre-vaccination era [13,38], but the mark-
edly higher mortality rate for girls in the age group for Penta sug-
gests that the vaccine increases female mortality relative to male
mortality. After 9 months of age the effect may be counteracted
by vaccination with MV+YF. Lower female than male mortality
after MV+YF has also been observed in prior studies from the Gam-
bia and Guinea-Bissau [19,39].
4.4. Interpretation
For several reasons the sex-differential effect of Penta is not
likely to be due to differences in mortality rates for boys and girls
at different ages. First, in the present study, the F/M MRR after
Penta did not vary by the age of vaccination. Second, mortality
for children who received OPV only did not differ by sex, while
there was marked higher mortality in girls who also received
Penta. Third, among children who had not been registered at a vac-
cination session after 42 days of age, girls did not have higher mor-
tality than boys between 6 weeks and 8 months of age. Data from
other studies have also supported that the increased female versus
male mortality rate ratio is not an age effect: In an RCT of early MV
4 weeks after DTP3, mortality was higher in girls than in boys in
the control group, who had DTP3 as their most recent vaccine,
but lower in girls in the intervention group which received MV
4556 A.B. Fisker et al. / Vaccine 34 (2016) 4551–4557[6], and in the pre-vaccination era, the mortality of boys and girls
did not differ in the age groups where children now receive Penta
and MV [13,38]. Fourth, when the sequence of vaccines is altered
and DTP is given after MV, girls again have higher mortality
[40–42].
4.5. Implications
The effect of DTP on all cause-mortality was not tested prior to
the vaccine being rolled out in low-income countries in the 1970s.
The present study adds to the large body of evidence indicating
that female mortality is higher than male mortality after
vaccination with inactivated DTP-containing vaccines. Since the
female/male MRR did not differ in the pre-vaccination era and
did not differ among children who had not been registered at a
vaccination contact for Penta after 42 days of age, this supports
that DTP-containing vaccines are associated with increased
mortality for females relative to males.
Our study has important implications for the vaccination pro-
gramme. First, immunisation programmes cannot be evaluated
merely by coverage and incidence of targeted diseases. The impact
on overall mortality of both girls and boys should be assessed. The
coverage of DTP3 currently serves as the main indicator for moni-
toring the immunisation programme [43] and globally more chil-
dren are missing MV than DTP3 [44]. This does not favour the
health of girls. To change the vaccination programme, SAGE has
called for RCTs [45]. While randomised trials are certainly justified,
it has been 15 years since the first concerns about increased mor-
tality following DTP vaccination were raised [5] and observational
studies are at present the best evidence we have. Similar observa-
tional studies could be undertaken in other HDSS settings where
linkage to the vaccination registries exist [46,47] or can be estab-
lished. Provided consistent findings, such data would emphasise
the urgency of improving the vaccination programme.
Second, it is imperative, that new vaccines intended for intro-
duction in the vaccination programme are evaluated for their effect
on all cause child mortality overall and separately for boys and
girls. For example, the new RTS,S malaria vaccine was recently
linked to excess female mortality [48,49].
Future vaccination programmes should seek to abrogate nega-
tive NSEs of Penta. The negative effect of DTP-containing vaccines
for girls can apparently be reversed by providing a live MV shortly
after the last dose of DTP. However, there may be more to gain if
the negative effect of Penta in girls could be prevented also during
the first months of life. A strategy which might look promising,
could be to co-administer a second dose of BCG with the second
or third dose of Penta since studies have indicated that co-
administered BCG+DTP is associated with lower female mortality
than DTP-only [12,50]. An alternative could be to delay vaccination
with DTP-containing vaccines in girls. The same vaccination sched-
ule may not be optimal for boys and girls, and sex-differential
vaccination programmes should be considered.
4.6. Conclusion
While the shift from DTP to Penta added protection against two
further pathogens, the problem of increased mortality for females
relative to males following DTP-containing vaccinations has not
been solved. To improve child health, we need to shift from mon-
itoring the immunisation programme by DTP3 coverage to assess-
ing the impact of vaccines on mortality of boys and girls.Conflicts of interest
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